Novo Nordisk has invited OSU and a limited number of leading academic and medical center research institutions in the Great Lakes region to submit proposals for nonclinical diabetes and obesity research related to new biological therapeutics and targets. Early exploration awards (up to $125K in direct costs per year for 2 years plus full indirect costs) and later stage Proof of Principle awards (up to $250K in direct costs per year for 2 years plus full indirect costs) are available. Non-confidential pre-proposals are due by February 15, 2013. Novo Nordisk will select a limited number of proposals to be presented at a two day science forum at the University of Chicago Gleacher Center on April 16 and 17. Final award selection will be made following the close of the science forum, and full proposals will need to be submitted at that time.
Contact Brenda Akins
(247-1973) for the full funding announcement and pre-proposal form.